FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1240-1241 May 4, 1995 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Rosenthal, N. PubMed Citation

To the Editor: As a physician and a molecular biologist, I am struck by the Journal's series on molecular medicine. To my ear, the series is marked by a kind of overexuberance that belongs in a sales pitch for biotechnology investors, not in a reasoned review for physicians. For example, an article on gene regulation (Oct. 6 issue)¹ concludes, "Knowing the molecular details of these processes will ultimately allow us to rewrite the genetic language when it goes awry." This is a remarkably optimistic view. The distance between understanding molecular details and developing a clinically useful intervention is vast and . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.